BrainQ's goal is to develop therapies that target damaged neuronal networks and facilitate neurorecovery. The company is developing a cloud-based platform to map brain network activity using explanatory machine-learning algorithms to extract biological insights that translate into precision therapies. The therapies are delivered via an investigational noninvasive portable medical device that creates a frequency-tuned low-intensity electromagnetic field.
In February 2021, the company received FDA breakthrough status for its device for reducing disability following stroke. The designation, which was based on BrainQ's latest randomized controlled clinical trial results for ischemic stroke patients, will allow BrainQ to work with the FDA to expedite the development and clearance process of BrainQ's device.
BrainQ is based at the Hebrew University campus in Givat Ram, Jerusalem.